Labopharm (DDSS) Posts Q3 Loss of 12c, Down 1c Y/Y
More News related to DDSS
- Labopharm to present at Dundee Emerging Growth Summit
- Labopharm's novel trazodone formulation subject of publication in peer-reviewed medical journal
- Labopharm (DDSS) Posts Q3 Loss of 12c, Down 1c Y/Y
- Labopharm Reports Results for Third Quarter Fiscal 2009
- Labopharm to host conference call Friday, November 6, 2009 at 10:00 a.m. (ET)
Labopharm Inc. (NASDAQ: DDSS) reports Q3 loss of $0.12, compared to ($0.11) in the same quarter last year. Revenue for the quarter was $5.2 million, versus $3.9 million in Q308.
Related Categories
EarningsStocks Mentioned
+0.01Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
